Novo's early responders play, cleaning house at the FDA, IsoMorphic's $2.1B round, and more!
sharp! at ECO the main buzz was around precision obesity and i think in the next year or two we’ll get phenotypic data that allows for better segmentation of the drugs. will be interesting to see how that affects sales forecasting
That will be a big plus for patients. Curious to see how it will affect pricing.
sharp! at ECO the main buzz was around precision obesity and i think in the next year or two we’ll get phenotypic data that allows for better segmentation of the drugs. will be interesting to see how that affects sales forecasting
That will be a big plus for patients. Curious to see how it will affect pricing.